
## **Yanling Feng**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4064188/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of Gynecologic Oncology, 2022, 33, .	2.2	1
2	Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 439-449.	10.7	115
3	Perineural Invasion Should Be Regarded as an Intermediate-Risk Factor for Recurrence in Surgically Treated Cervical Cancer: A Propensity Score Matching Study. Disease Markers, 2021, 2021, 1-8.	1.3	5
4	The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer. Journal of Gynecologic Oncology, 2021, 32, e40.	2.2	12
5	Preoperative Evaluation of Perineural Invasion in Cervical Cancer: Development and Independent Validation of a Novel Predictive Nomogram. Frontiers in Oncology, 2021, 11, 774459.	2.8	0
6	Minimally invasive surgery vs laparotomy for early stage cervical cancer: A propensity scoreâ€matched cohort study. Cancer Medicine, 2020, 9, 9236-9245.	2.8	6
7	Potential risks in sentinel lymph node biopsy for cervical cancer: a single-institution pilot study. World Journal of Surgical Oncology, 2020, 18, 133.	1.9	4
8	Prognostic value of prostaglandin I2 synthase and its correlation with tumor-infiltrating immune cells in lung cancer, ovarian cancer, and gastric cancer. Aging, 2020, 12, 9658-9685.	3.1	30
9	A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study. Journal of Gynecologic Oncology, 2020, 31, e61.	2.2	6
10	Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept. Journal of Gynecologic Oncology, 2020, 31, e86.	2.2	22
11	Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis. Advances in Therapy, 2019, 36, 3368-3380.	2.9	14
12	Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy. Oncolmmunology, 2019, 8, e1528411.	4.6	16
13	The Role of GOLPH3L in the Prognosis and NACT response in Cervical Cancer. Journal of Cancer, 2017, 8, 443-454.	2.5	6
14	High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma. PLoS ONE, 2016, 11, e0167449.	2.5	45
15	Neoadjuvant chemotherapy followed by conization to spare fertility in cases of locally advanced cervical cancer: A case report and review of the literature. Molecular and Clinical Oncology, 2016, 5, 411-416.	1.0	8
16	Low initial human papillomavirus viral load may indicate worse prognosis in patients with cervical carcinoma treated with surgery. Journal of Gynecologic Oncology, 2015, 26, 111.	2.2	25
17	GOLPH3L is a Novel Prognostic Biomarker for Epithelial Ovarian Cancer. Journal of Cancer, 2015, 6, 893-900.	2.5	16
18	Prognostic and Safety Roles in Laparoscopic Versus Abdominal Radical Hysterectomy in Cervical Cancer: A Meta-analysis. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2015, 25, 990-998.	1.0	83

#	Article	IF	CITATIONS
19	The outcome and efficacy of adjuvant chemotherapy alone in patients with stage IIIA endometrial carcinoma with solitary adnexal involvement: A retrospective single-institution study. Gynecologic Oncology, 2014, 135, 446-450.	1.4	3